All In Biotech

Drug Trial Radar · NCT04650399

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

A Multicenter, Randomized, Controlled, Double Blinded Pivotal Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Adolescents Aged 12 Years to <18 Years

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 754 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

754

Actual

Start

Feb 14, 2022

Primary completion

Mar 14, 2023

Study completion Feb 16, 2024

Sponsor

Lead sponsor
Butantan InstituteGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Valneva Austria GmbH
First posted
Dec 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The dose of VLA1553 or control was administered as single vaccination on Day 1. Overall, approximately 750 male and female participants aged 12 years to \<18 years were enrolled into the study. After completion of the trial, a Post Trial Access program was performed to offer the VLA1553 vaccine to all placebo recipients.

Conditions

  • Chikungunya

Interventions

  • ActiveBiological

    Single intramuscular vaccination on Day 1 with VLA1553, a lyophilized live-attenuated Chikungunya vaccine candidate 1x10E4 TCID50 per dose (0.5 mL)

  • PlaceboBiological

    Single intramuscular vaccination on Day 1 with Phosphate-Buffered Saline (PBS) as placebo (0.5 mL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SeroprotectionTime frame: On study Day 29,which is 28 days after single vaccination

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Centro de Pesquisa Clínica da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul - UFMS

    Campo Grande, Brazil

  • Centro de Estudos do Instituto de Infectologia Emílio Ribas

    São Paulo, Brazil

  • CECOR - Centro Oncológico de Roraima

    Boa Vista, Acre, Brazil

  • Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

    Manaus, Amazonas, Brazil

  • Núcleo de Medicina Tropical - Universidade Federal do Ceará

    Fortaleza, Ceará, Brazil

  • Associação Obras Sociais Irmã Dulce / Centro de Pesquisa Clínica - CPEC

    Salvador, Estado de Bahia, Brazil

  • Centro de Pesquisa e Desenvolvimento de Fármacos (CPDF) - Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas

    Belo Horizonte, Minas Gerais, Brazil

  • Real Hospital Português de Beneficência em Pernambuco

    Recife, Pernambuco, Brazil

  • Faculdade de Medicina de São José do Rio Preto - FAMERP

    São José do Rio Preto, São Paulo, Brazil

  • Centro de Pesquisas Clínicas Universidade Federal Sergipe

    Aracaju, Sergipe, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.